Silencing of LncRNA PVT1 inhibits the proliferation, migration and fibrosis of high glucose-induced mouse mesangial cells via targeting microRNA-93-5p.
LncRNA-PVT1
PI3K/Akt/mTOR pathway
diabetic nephropathy
miR-93-5p
mouse mesangial cells
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
29 05 2020
29 05 2020
Historique:
received:
06
01
2020
revised:
16
04
2020
accepted:
20
04
2020
pubmed:
25
4
2020
medline:
25
4
2020
entrez:
25
4
2020
Statut:
ppublish
Résumé
The present study aimed to investigate the regulatory role of long non-coding RNA plasmacytoma variant translocation 1 (PVT1) on high glucose (HG)-induced mouse mesangial cells (MMCs). PVT1 expression in diabetic nephropathy (DN) mice and HG-induced MMCs was detected by qRT-PCR. EdU and Colony formation, Annexin V-PI staining, Muse cell cycle, Scratch, and Transwell assays were performed to detect the cell proliferation, apoptosis, cell cycle, migration, and invasion, respectively. The contents of fibrosis factors in cell-culture supernatants were detected by enzyme-linked immunosorbent assay (ELISA). Western blot was performed to detect the expression of factors involved in apoptosis, cell cycle, migration and invasion, fibrosis, and PI3K/Akt/mTOR pathway. The targeting relation between miR-93-5p and PVT1 was predicted by StarBase3.0 (an online software for analyzing the targeting relationship) and identified by Dual-luciferase reporter (DLR) assay. PVT1 was overexpressed in DN kidney tissues and HG-induced MMCs. HG-induced MMCs exhibited significantly increased EdU-positive cells, cell colonies, S and G2/M phase cells, migration and invasion ability, and contents of fibrosis factors, as well as significantly decreased apoptosis rate compared with NG-induced MMCs. HG significantly up-regulated Bcl-2, CyclinD1, CDK4, N-cadherin, vimentin, Col. IV, FN, TGF-β1 and PAI-1, and down-regulated Bax, cleaved caspase-3, cleaved PARP, and E-cadherin in MMCs. Silencing of PVT1 eliminated the effects of HG in MMCs and blocked PI3K/Akt/mTOR pathway. MiR-93-5p was a target of PVT1, which eliminated the effects of PVT1 on HG-induced MMCs. PVT1 silencing inhibited the proliferation, migration, invasion and fibrosis, promoted the apoptosis, and blocked PI3K/Akt/mTOR pathway in HG-induced MMCs via up-regulating miR-93-5p.
Identifiants
pubmed: 32329508
pii: 222762
doi: 10.1042/BSR20194427
pmc: PMC7199453
pii:
doi:
Types de publication
Journal Article
Retracted Publication
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : RetractionIn
Informations de copyright
© 2020 The Author(s).
Références
Sci Rep. 2016 Mar 31;6:23884
pubmed: 27029904
Cell. 2010 Oct 1;143(1):46-58
pubmed: 20887892
Mol Cell Endocrinol. 2016 May 5;426:136-45
pubmed: 26923441
J Endocrinol. 2015 Jan;224(1):R15-30
pubmed: 25349246
Biochem Biophys Res Commun. 2013 Apr 19;433(4):359-61
pubmed: 23541575
Oncol Lett. 2016 Mar;11(3):1745-1749
pubmed: 26998071
Oncotarget. 2016 Mar 8;7(10):11553-66
pubmed: 26872375
Oncogene. 2011 Apr 21;30(16):1956-62
pubmed: 21151178
Diabetes. 2007 Apr;56(4):975-83
pubmed: 17395743
J Cancer. 2017 Mar 7;8(5):870-879
pubmed: 28382150
Am J Transl Res. 2016 Nov 15;8(11):5025-5034
pubmed: 27904703
Nat Commun. 2016 Jun 28;7:12076
pubmed: 27350436
Behav Brain Res. 2016 May 15;305:265-77
pubmed: 26971628
Kidney Int Suppl. 2005 Sep;(98):S69-75
pubmed: 16108975
PLoS One. 2013 Oct 25;8(10):e77468
pubmed: 24204837
J Pharmacol Sci. 2018 Apr;136(4):218-227
pubmed: 29551286
Expert Opin Investig Drugs. 2017 Jun;26(6):741-750
pubmed: 28468519
Oncol Rep. 2017 Oct;38(4):2408-2416
pubmed: 28791407
Oncotarget. 2015 Jun 20;6(17):14993-5007
pubmed: 25915427
Cell Physiol Biochem. 2017;41(3):1035-1043
pubmed: 28222433
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6929-35
pubmed: 25400777
Cancer Res. 2011 Jun 1;71(11):3852-62
pubmed: 21558391
J Cell Physiol. 2018 May;233(5):4044-4055
pubmed: 28657147
PLoS One. 2011 Apr 22;6(4):e18671
pubmed: 21526116
Endocrine. 2016 Oct;54(1):81-92
pubmed: 27083175
Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1159-1166
pubmed: 28382439
Diabetes. 2007 Dec;56(12):3027-32
pubmed: 17881614
J Med Chem. 2017 Nov 9;60(21):8847-8857
pubmed: 28994286
J Cell Mol Med. 2017 Nov;21(11):2732-2747
pubmed: 28444861
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Mol Cancer Res. 2008 Feb;6(2):212-21
pubmed: 18314482
J Clin Invest. 2012 Nov;122(11):3990-4002
pubmed: 23093776
Cell Physiol Biochem. 2018;46(2):591-608
pubmed: 29617692
J Biol Chem. 2010 Jul 23;285(30):23457-65
pubmed: 20501654
J Histochem Cytochem. 2013 Jun;61(6):433-43
pubmed: 23456824
Saudi J Kidney Dis Transpl. 2006 Dec;17(4):481-90
pubmed: 17186681
Sci Rep. 2017 Jun 23;7(1):4145
pubmed: 28646178
Phytomedicine. 2015 Nov 15;22(12):1071-8
pubmed: 26547529
Diabetologia. 2013 Mar;56(3):444-56
pubmed: 23135222
Exp Ther Med. 2017 Feb;13(2):581-587
pubmed: 28352334